APO Research
Talk to an analyst

APO RESEARCH · REPORT

CD40 Ligand

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global CD40 Ligand Industry Growth and Trends Forecast to 2032

19 December 202599 pages

Choose your research edition.

Industry ResearchCD40 Ligand Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal CD40 Ligand Industry Growth and Trends Forecast to 203299 pages · $3,450 USDMarket StructureGlobal CD40 Ligand Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal CD40 Ligand Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal CD40 Ligand Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global CD40 Ligand market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for CD40 Ligand is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for CD40 Ligand is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for CD40 Ligand is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of CD40 Ligand include Biogen, Inc., XL-protein GmbH, Targovax AS, MedImmune, LLC, Juno Therapeutics Inc., ImmuNext, Inc., eTheRNA Immunotherapies NV and Bristol-Myers Squibb Company, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global CD40 Ligand market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The CD40 Ligand market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global CD40 Ligand market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to CD40 Ligand.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global CD40 Ligand market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

CD40 Ligand Market by Company

Biogen, Inc.

XL-protein GmbH

Targovax AS

MedImmune, LLC

Juno Therapeutics Inc.

ImmuNext, Inc.

eTheRNA Immunotherapies NV

Bristol-Myers Squibb Company

CD40 Ligand Segment by Type

ISF-35

MegaCD40L

MEDI-4920

LOAd-700

Others

CD40 Ligand Segment by Application

Hepatitis B

Ovarian Cancer

Liver Cancer

Bladder Cancer

Others

CD40 Ligand Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global CD40 Ligand market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of CD40 Ligand and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of CD40 Ligand.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of CD40 Ligand manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of CD40 Ligand in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of ISF-35 Table 2. Major Company of MegaCD40L Table 3. Major Company of MEDI-4920 Table 4. Major Company of LOAd-700 Table 5. Major Company of Others Table 6. Global CD40 Ligand Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global CD40 Ligand Sales by Type (2021-2026) & (K Units) Table 8. Global CD40 Ligand Sales Market Share in Volume by Type (2021-2026) Table 9. Global CD40 Ligand Sales by Type (2021-2026) & (US$ Million) Table 10. Global CD40 Ligand Sales Market Share in Value by Type (2021-2026) Table 11. Global CD40 Ligand Price by Type (2021-2026) & (US$/Unit) Table 12. Global CD40 Ligand Sales by Type (2027-2032) & (K Units) Table 13. Global CD40 Ligand Sales Market Share in Volume by Type (2027-2032) Table 14. Global CD40 Ligand Sales by Type (2027-2032) & (US$ Million) Table 15. Global CD40 Ligand Sales Market Share in Value by Type (2027-2032) Table 16. Global CD40 Ligand Price by Type (2027-2032) & (US$/Unit) Table 17. North America CD40 Ligand Sales by Type (2021-2026) & (K Units) Table 18. North America CD40 Ligand Sales by Type (2021-2026) & (US$ Million) Table 19. Europe CD40 Ligand Sales by Type (2021-2026) & (K Units) Table 20. Europe CD40 Ligand Sales by Type (2021-2026) & (US$ Million) Table 21. Asia-Pacific CD40 Ligand Sales by Type (2021-2026) & (K Units) Table 22. Asia-Pacific CD40 Ligand Sales by Type (2021-2026) & (US$ Million) Table 23. Latin America CD40 Ligand Sales by Type (2021-2026) & (K Units) Table 24. Latin America CD40 Ligand Sales by Type (2021-2026) & (US$ Million) Table 25. Middle East and Africa CD40 Ligand Sales by Type (2021-2026) & (K Units) Table 26. Middle East and Africa CD40 Ligand Sales by Type (2021-2026) & (US$ Million) Table 27. CD40 Ligand Industry Trends Table 28. CD40 Ligand Industry Drivers Table 29. CD40 Ligand Industry Opportunities and Challenges Table 30. CD40 Ligand Industry Restraints Table 31. Global CD40 Ligand Sales Revenue by Company (US$ Million) & (2021-2026) Table 32. Global CD40 Ligand Revenue Market Share by Company (2021-2026) Table 33. Global CD40 Ligand Sales by Company (2021-2026) & (K Units) Table 34. Global CD40 Ligand Sales Share by Company (2021-2026) Table 35. Global CD40 Ligand Market Price by Company (2021-2026) & (US$/Unit) Table 36. Global CD40 Ligand Industry Company Ranking, 2024 VS 2025 VS 2026 Table 37. Global CD40 Ligand Major Company Production Sites and Headquarters Table 38. Global CD40 Ligand Company, Product Type & Application Table 39. Global CD40 Ligand Company Establishment Date Table 40. Global Company Market Concentration Ratio (CR5 and HHI) Table 41. Global CD40 Ligand by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 42. Global CD40 Ligand Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 43. Global CD40 Ligand Sales by Region (2021-2026) & (K Units) Table 44. Global CD40 Ligand Sales Market Share in Volume by Region (2021-2026) Table 45. Global CD40 Ligand Sales by Region (2021-2026) & (US$ Million) Table 46. Global CD40 Ligand Sales Market Share in Value by Region (2021-2026) Table 47. Global CD40 Ligand Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 48. Global CD40 Ligand Sales by Region (2027-2032) & (K Units) Table 49. Global CD40 Ligand Sales Market Share in Volume by Region (2027-2032) Table 50. Global CD40 Ligand Sales by Region (2027-2032) & (US$ Million) Table 51. Global CD40 Ligand Sales Market Share in Value by Region (2027-2032) Table 52. Global CD40 Ligand Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 53. Global CD40 Ligand Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 54. Global CD40 Ligand Sales by Application (2021-2026) & (K Units) Table 55. Global CD40 Ligand Sales Market Share in Volume by Application (2021-2026) Table 56. Global CD40 Ligand Sales by Application (2021-2026) & (US$ Million) Table 57. Global CD40 Ligand Sales Market Share in Value by Application (2021-2026) Table 58. Global CD40 Ligand Price by Application (2021-2026) & (US$/Unit) Table 59. Global CD40 Ligand Sales by Application (2027-2032) & (K Units) Table 60. Global CD40 Ligand Sales Market Share in Volume by Application (2027-2032) Table 61. Global CD40 Ligand Sales by Application (2027-2032) & (US$ Million) Table 62. Global CD40 Ligand Sales Market Share in Value by Application (2027-2032) Table 63. Global CD40 Ligand Price by Application (2027-2032) & (US$/Unit) Table 64. North America CD40 Ligand Sales by Application (2021-2026) & (K Units) Table 65. North America CD40 Ligand Sales by Application (2021-2026) & (US$ Million) Table 66. Europe CD40 Ligand Sales by Application (2021-2026) & (K Units) Table 67. Europe CD40 Ligand Sales by Application (2021-2026) & (US$ Million) Table 68. Asia-Pacific CD40 Ligand Sales by Application (2021-2026) & (K Units) Table 69. Asia-Pacific CD40 Ligand Sales by Application (2021-2026) & (US$ Million) Table 70. Latin America CD40 Ligand Sales by Application (2021-2026) & (K Units) Table 71. Latin America CD40 Ligand Sales by Application (2021-2026) & (US$ Million) Table 72. Middle East and Africa CD40 Ligand Sales by Application (2021-2026) & (K Units) Table 73. Middle East and Africa CD40 Ligand Sales by Application (2021-2026) & (US$ Million) Table 74. Biogen, Inc. Company Information Table 75. Biogen, Inc. Business Overview Table 76. Biogen, Inc. CD40 Ligand Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Biogen, Inc. CD40 Ligand Product Portfolio Table 78. Biogen, Inc. Recent Development Table 79. XL-protein GmbH Company Information Table 80. XL-protein GmbH Business Overview Table 81. XL-protein GmbH CD40 Ligand Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. XL-protein GmbH CD40 Ligand Product Portfolio Table 83. XL-protein GmbH Recent Development Table 84. Targovax AS Company Information Table 85. Targovax AS Business Overview Table 86. Targovax AS CD40 Ligand Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Targovax AS CD40 Ligand Product Portfolio Table 88. Targovax AS Recent Development Table 89. MedImmune, LLC Company Information Table 90. MedImmune, LLC Business Overview Table 91. MedImmune, LLC CD40 Ligand Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. MedImmune, LLC CD40 Ligand Product Portfolio Table 93. MedImmune, LLC Recent Development Table 94. Juno Therapeutics Inc. Company Information Table 95. Juno Therapeutics Inc. Business Overview Table 96. Juno Therapeutics Inc. CD40 Ligand Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Juno Therapeutics Inc. CD40 Ligand Product Portfolio Table 98. Juno Therapeutics Inc. Recent Development Table 99. ImmuNext, Inc. Company Information Table 100. ImmuNext, Inc. Business Overview Table 101. ImmuNext, Inc. CD40 Ligand Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. ImmuNext, Inc. CD40 Ligand Product Portfolio Table 103. ImmuNext, Inc. Recent Development Table 104. eTheRNA Immunotherapies NV Company Information Table 105. eTheRNA Immunotherapies NV Business Overview Table 106. eTheRNA Immunotherapies NV CD40 Ligand Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. eTheRNA Immunotherapies NV CD40 Ligand Product Portfolio Table 108. eTheRNA Immunotherapies NV Recent Development Table 109. Bristol-Myers Squibb Company Company Information Table 110. Bristol-Myers Squibb Company Business Overview Table 111. Bristol-Myers Squibb Company CD40 Ligand Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Bristol-Myers Squibb Company CD40 Ligand Product Portfolio Table 113. Bristol-Myers Squibb Company Recent Development Table 114. North America CD40 Ligand Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 115. North America CD40 Ligand Sales by Country (2021-2026) & (K Units) Table 116. North America CD40 Ligand Sales Market Share by Country (2021-2026) Table 117. North America CD40 Ligand Sales Forecast by Country (2027-2032) & (K Units) Table 118. North America CD40 Ligand Sales Market Share Forecast by Country (2027-2032) Table 119. North America CD40 Ligand Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 120. North America CD40 Ligand Market Size by Country (2021-2026) & (US$ Million) Table 121. North America CD40 Ligand Market Share by Country (2021-2026) Table 122. North America CD40 Ligand Market Size Forecast by Country (2027-2032) & (US$ Million) Table 123. North America CD40 Ligand Market Share Forecast by Country (2027-2032) Table 124. Europe CD40 Ligand Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 125. Europe CD40 Ligand Sales by Country (2021-2026) & (K Units) Table 126. Europe CD40 Ligand Sales Market Share by Country (2021-2026) Table 127. Europe CD40 Ligand Sales Forecast by Country (2027-2032) & (K Units) Table 128. Europe CD40 Ligand Sales Market Share Forecast by Country (2027-2032) Table 129. Europe CD40 Ligand Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 130. Europe CD40 Ligand Market Size by Country (2021-2026) & (US$ Million) Table 131. Europe CD40 Ligand Market Share by Country (2021-2026) Table 132. Europe CD40 Ligand Market Size Forecast by Country (2027-2032) & (US$ Million) Table 133. Europe CD40 Ligand Market Share Forecast by Country (2027-2032) Table 134. Asia-Pacific CD40 Ligand Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 135. Asia-Pacific CD40 Ligand Sales by Country (2021-2026) & (K Units) Table 136. Asia-Pacific CD40 Ligand Sales Market Share by Country (2021-2026) Table 137. Asia-Pacific CD40 Ligand Sales Forecast by Country (2027-2032) & (K Units) Table 138. Asia-Pacific CD40 Ligand Sales Market Share Forecast by Country (2027-2032) Table 139. Asia-Pacific CD40 Ligand Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 140. Asia-Pacific CD40 Ligand Market Size by Country (2021-2026) & (US$ Million) Table 141. Asia-Pacific CD40 Ligand Market Share by Country (2021-2026) Table 142. Asia-Pacific CD40 Ligand Market Size Forecast by Country (2027-2032) & (US$ Million) Table 143. Asia-Pacific CD40 Ligand Market Share Forecast by Country (2027-2032) Table 144. Latin America CD40 Ligand Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 145. Latin America CD40 Ligand Sales by Country (2021-2026) & (K Units) Table 146. Latin America CD40 Ligand Sales Market Share by Country (2021-2026) Table 147. Latin America CD40 Ligand Sales Forecast by Country (2027-2032) & (K Units) Table 148. Latin America CD40 Ligand Sales Market Share Forecast by Country (2027-2032) Table 149. Latin America CD40 Ligand Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 150. Latin America CD40 Ligand Market Size by Country (2021-2026) & (US$ Million) Table 151. Latin America CD40 Ligand Market Share by Country (2021-2026) Table 152. Latin America CD40 Ligand Market Size Forecast by Country (2027-2032) & (US$ Million) Table 153. Latin America CD40 Ligand Market Share Forecast by Country (2027-2032) Table 154. Middle East and Africa CD40 Ligand Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 155. Middle East and Africa CD40 Ligand Sales by Country (2021-2026) & (K Units) Table 156. Middle East and Africa CD40 Ligand Sales Market Share by Country (2021-2026) Table 157. Middle East and Africa CD40 Ligand Sales Forecast by Country (2027-2032) & (K Units) Table 158. Middle East and Africa CD40 Ligand Sales Market Share Forecast by Country (2027-2032) Table 159. Middle East and Africa CD40 Ligand Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 160. Middle East and Africa CD40 Ligand Market Size by Country (2021-2026) & (US$ Million) Table 161. Middle East and Africa CD40 Ligand Market Share by Country (2021-2026) Table 162. Middle East and Africa CD40 Ligand Market Size Forecast by Country (2027-2032) & (US$ Million) Table 163. Middle East and Africa CD40 Ligand Market Share Forecast by Country (2027-2032) Table 164. Key Raw Materials Table 165. Raw Materials Key Suppliers Table 166. CD40 Ligand Distributors List Table 167. CD40 Ligand Customers List Table 168. Research Programs/Design for This Report Table 169. Authors List of This Report Table 170. Secondary Sources Table 171. Primary Sources List of Figures Figure 1. CD40 Ligand Image Figure 2. Global CD40 Ligand Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global CD40 Ligand Market Size (2021-2032) & (US$ Million) Figure 4. Global CD40 Ligand Sales (2021-2032) & (K Units) Figure 5. ISF-35 Image Figure 6. Global ISF-35 Sales YoY Growth (2021-2032) & (K Units) Figure 7. MegaCD40L Image Figure 8. Global MegaCD40L Sales YoY Growth (2021-2032) & (K Units) Figure 9. MEDI-4920 Image Figure 10. Global MEDI-4920 Sales YoY Growth (2021-2032) & (K Units) Figure 11. LOAd-700 Image Figure 12. Global LOAd-700 Sales YoY Growth (2021-2032) & (K Units) Figure 13. Others Image Figure 14. Global Others Sales YoY Growth (2021-2032) & (K Units) Figure 15. Global CD40 Ligand Market Size Overview by Type (2021-2032) & (US$ Million) Figure 16. Global CD40 Ligand Market Share by Type 2025 VS 2032 Figure 17. North America CD40 Ligand Sales Market Share in Volume by Type in 2025 Figure 18. North America CD40 Ligand Sales Market Share in Value by Type in 2025 Figure 19. Europe CD40 Ligand Sales Market Share in Volume by Type in 2025 Figure 20. Europe CD40 Ligand Sales Market Share in Value by Type in 2025 Figure 21. Asia-Pacific CD40 Ligand Sales Market Share in Volume by Type in 2025 Figure 22. Asia-Pacific CD40 Ligand Sales Market Share in Value by Type in 2025 Figure 23. Latin America CD40 Ligand Sales Market Share in Volume by Type in 2025 Figure 24. Latin America CD40 Ligand Sales Market Share in Value by Type in 2025 Figure 25. Middle East and Africa CD40 Ligand Sales Market Share in Volume by Type in 2025 Figure 26. Middle East and Africa CD40 Ligand Sales Market Share in Value by Type in 2025 Figure 27. Global Top 5 and 10 CD40 Ligand Players Market Share by Revenue in 2025 Figure 28. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 29. Hepatitis B Image Figure 30. Global Hepatitis B Sales YoY Growth (2021-2032) & (K Units) Figure 31. Ovarian Cancer Image Figure 32. Global Ovarian Cancer Sales YoY Growth (2021-2032) & (K Units) Figure 33. Liver Cancer Image Figure 34. Global Liver Cancer Sales YoY Growth (2021-2032) & (K Units) Figure 35. Bladder Cancer Image Figure 36. Global Bladder Cancer Sales YoY Growth (2021-2032) & (K Units) Figure 37. Others Image Figure 38. Global Others Sales YoY Growth (2021-2032) & (K Units) Figure 39. Global CD40 Ligand Market Size Overview by Application (2021-2032) & (US$ Million) Figure 40. Global CD40 Ligand Market Share by Application 2025 VS 2032 Figure 41. North America CD40 Ligand Sales Market Share in Volume by Application in 2025 Figure 42. North America CD40 Ligand Sales Market Share in Value by Application in 2025 Figure 43. Europe CD40 Ligand Sales Market Share in Volume by Application in 2025 Figure 44. Europe CD40 Ligand Sales Market Share in Value by Application in 2025 Figure 45. Asia-Pacific CD40 Ligand Sales Market Share in Volume by Application in 2025 Figure 46. Asia-Pacific CD40 Ligand Sales Market Share in Value by Application in 2025 Figure 47. Latin America CD40 Ligand Sales Market Share in Volume by Application in 2025 Figure 48. Latin America CD40 Ligand Sales Market Share in Value by Application in 2025 Figure 49. Middle East and Africa CD40 Ligand Sales Market Share in Volume by Application in 2025 Figure 50. Middle East and Africa CD40 Ligand Sales Market Share in Value by Application in 2025 Figure 51. North America CD40 Ligand Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 52. North America CD40 Ligand Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. North America CD40 Ligand Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. North America CD40 Ligand Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Europe CD40 Ligand Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 56. Europe CD40 Ligand Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Europe CD40 Ligand Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Europe CD40 Ligand Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Asia-Pacific CD40 Ligand Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 60. Asia-Pacific CD40 Ligand Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific CD40 Ligand Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Asia-Pacific CD40 Ligand Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Latin America CD40 Ligand Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 64. Latin America CD40 Ligand Sales Share by Country: 2021 VS 2025 VS 2032 Figure 65. Latin America CD40 Ligand Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 66. Latin America CD40 Ligand Market Share by Country: 2021 VS 2025 VS 2032 Figure 67. Middle East and Africa CD40 Ligand Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 68. Middle East and Africa CD40 Ligand Sales Share by Country: 2021 VS 2025 VS 2032 Figure 69. Middle East and Africa CD40 Ligand Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 70. Middle East and Africa CD40 Ligand Market Share by Country: 2021 VS 2025 VS 2032 Figure 71. CD40 Ligand Value Chain Figure 72. Key Raw Materials Price Figure 73. Manufacturing Cost Structure Figure 74. CD40 Ligand Production Mode & Process Figure 75. Direct Comparison with Distribution Share Figure 76. Distributors Profiles Figure 77. Years Considered Figure 78. Research Process Figure 79. Key Executives Interviewed

Scope & coverage.

Types
  • ISF-35
  • MegaCD40L
  • MEDI-4920
  • LOAd-700
  • Others
Applications
  • Hepatitis B
  • Ovarian Cancer
  • Liver Cancer
  • Bladder Cancer
  • Others
Companies covered
  • Biogen, Inc.
  • XL-protein GmbH
  • Targovax AS
  • MedImmune, LLC
  • Juno Therapeutics Inc.
  • ImmuNext, Inc.
  • eTheRNA Immunotherapies NV
  • Bristol-Myers Squibb Company

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global CD40 Ligand Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global CD40 Ligand Sales Estimates and Forecasts (2021-2032)
  5. 1.3 CD40 Ligand Market by Type
  6. 1.3.1 ISF-35
  7. 1.3.2 MegaCD40L
  8. 1.3.3 MEDI-4920
  9. 1.3.4 LOAd-700
  10. 1.3.5 Others
  11. 1.4 Global CD40 Ligand Market Size by Type
  12. 1.4.1 Global CD40 Ligand Market Size Overview by Type (2021-2032)
  13. 1.4.2 Global CD40 Ligand Historic Market Size Review by Type (2021-2026)
  14. 1.4.3 Global CD40 Ligand Forecasted Market Size by Type (2027-2032)
  15. 1.5 Key Regions Market Size by Type
  16. 1.5.1 North America CD40 Ligand Sales Breakdown by Type (2021-2026)
  17. 1.5.2 Europe CD40 Ligand Sales Breakdown by Type (2021-2026)
  18. 1.5.3 Asia-Pacific CD40 Ligand Sales Breakdown by Type (2021-2026)
  19. 1.5.4 South America CD40 Ligand Sales Breakdown by Type (2021-2026)
  20. 1.5.5 Middle East and Africa CD40 Ligand Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 CD40 Ligand Industry Trends
  2. 2.2 CD40 Ligand Industry Drivers
  3. 2.3 CD40 Ligand Industry Opportunities and Challenges
  4. 2.4 CD40 Ligand Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by CD40 Ligand Revenue (2021-2026)
  2. 3.2 Global Top Players by CD40 Ligand Sales (2021-2026)
  3. 3.3 Global Top Players by CD40 Ligand Price (2021-2026)
  4. 3.4 Global CD40 Ligand Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global CD40 Ligand Major Company Production Sites & Headquarters
  6. 3.6 Global CD40 Ligand Company, Product Type & Application
  7. 3.7 Global CD40 Ligand Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global CD40 Ligand Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 CD40 Ligand Players Market Share by Revenue in 2025
  11. 3.8.3 2025 CD40 Ligand Tier 1, Tier 2, and Tier 3
4 CD40 Ligand Regional Status and Outlook
  1. 4.1 Global CD40 Ligand Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global CD40 Ligand Historic Market Size by Region
  3. 4.2.1 Global CD40 Ligand Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global CD40 Ligand Sales in Value by Region (2021-2026)
  5. 4.2.3 Global CD40 Ligand Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global CD40 Ligand Forecasted Market Size by Region
  7. 4.3.1 Global CD40 Ligand Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global CD40 Ligand Sales in Value by Region (2027-2032)
  9. 4.3.3 Global CD40 Ligand Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 CD40 Ligand by Application
  1. 5.1 CD40 Ligand Market by Application
  2. 5.1.1 Hepatitis B
  3. 5.1.2 Ovarian Cancer
  4. 5.1.3 Liver Cancer
  5. 5.1.4 Bladder Cancer
  6. 5.1.5 Others
  7. 5.2 Global CD40 Ligand Market Size by Application
  8. 5.2.1 Global CD40 Ligand Market Size Overview by Application (2021-2032)
  9. 5.2.2 Global CD40 Ligand Historic Market Size Review by Application (2021-2026)
  10. 5.2.3 Global CD40 Ligand Forecasted Market Size by Application (2027-2032)
  11. 5.3 Key Regions Market Size by Application
  12. 5.3.1 North America CD40 Ligand Sales Breakdown by Application (2021-2026)
  13. 5.3.2 Europe CD40 Ligand Sales Breakdown by Application (2021-2026)
  14. 5.3.3 Asia-Pacific CD40 Ligand Sales Breakdown by Application (2021-2026)
  15. 5.3.4 South America CD40 Ligand Sales Breakdown by Application (2021-2026)
  16. 5.3.5 Middle East and Africa CD40 Ligand Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Biogen, Inc.
  2. 6.1.1 Biogen, Inc. Company Information
  3. 6.1.2 Biogen, Inc. Business Overview
  4. 6.1.3 Biogen, Inc. CD40 Ligand Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Biogen, Inc. CD40 Ligand Product Portfolio
  6. 6.1.5 Biogen, Inc. Recent Developments
  7. 6.2 XL-protein GmbH
  8. 6.2.1 XL-protein GmbH Company Information
  9. 6.2.2 XL-protein GmbH Business Overview
  10. 6.2.3 XL-protein GmbH CD40 Ligand Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 XL-protein GmbH CD40 Ligand Product Portfolio
  12. 6.2.5 XL-protein GmbH Recent Developments
  13. 6.3 Targovax AS
  14. 6.3.1 Targovax AS Company Information
  15. 6.3.2 Targovax AS Business Overview
  16. 6.3.3 Targovax AS CD40 Ligand Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Targovax AS CD40 Ligand Product Portfolio
  18. 6.3.5 Targovax AS Recent Developments
  19. 6.4 MedImmune, LLC
  20. 6.4.1 MedImmune, LLC Company Information
  21. 6.4.2 MedImmune, LLC Business Overview
  22. 6.4.3 MedImmune, LLC CD40 Ligand Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 MedImmune, LLC CD40 Ligand Product Portfolio
  24. 6.4.5 MedImmune, LLC Recent Developments
  25. 6.5 Juno Therapeutics Inc.
  26. 6.5.1 Juno Therapeutics Inc. Company Information
  27. 6.5.2 Juno Therapeutics Inc. Business Overview
  28. 6.5.3 Juno Therapeutics Inc. CD40 Ligand Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Juno Therapeutics Inc. CD40 Ligand Product Portfolio
  30. 6.5.5 Juno Therapeutics Inc. Recent Developments
  31. 6.6 ImmuNext, Inc.
  32. 6.6.1 ImmuNext, Inc. Company Information
  33. 6.6.2 ImmuNext, Inc. Business Overview
  34. 6.6.3 ImmuNext, Inc. CD40 Ligand Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 ImmuNext, Inc. CD40 Ligand Product Portfolio
  36. 6.6.5 ImmuNext, Inc. Recent Developments
  37. 6.7 eTheRNA Immunotherapies NV
  38. 6.7.1 eTheRNA Immunotherapies NV Company Information
  39. 6.7.2 eTheRNA Immunotherapies NV Business Overview
  40. 6.7.3 eTheRNA Immunotherapies NV CD40 Ligand Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 eTheRNA Immunotherapies NV CD40 Ligand Product Portfolio
  42. 6.7.5 eTheRNA Immunotherapies NV Recent Developments
  43. 6.8 Bristol-Myers Squibb Company
  44. 6.8.1 Bristol-Myers Squibb Company Company Information
  45. 6.8.2 Bristol-Myers Squibb Company Business Overview
  46. 6.8.3 Bristol-Myers Squibb Company CD40 Ligand Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Bristol-Myers Squibb Company CD40 Ligand Product Portfolio
  48. 6.8.5 Bristol-Myers Squibb Company Recent Developments
7 North America by Country
  1. 7.1 North America CD40 Ligand Sales by Country
  2. 7.1.1 North America CD40 Ligand Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America CD40 Ligand Sales by Country (2021-2026)
  4. 7.1.3 North America CD40 Ligand Sales Forecast by Country (2027-2032)
  5. 7.2 North America CD40 Ligand Market Size by Country
  6. 7.2.1 North America CD40 Ligand Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America CD40 Ligand Market Size by Country (2021-2026)
  8. 7.2.3 North America CD40 Ligand Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe CD40 Ligand Sales by Country
  2. 8.1.1 Europe CD40 Ligand Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe CD40 Ligand Sales by Country (2021-2026)
  4. 8.1.3 Europe CD40 Ligand Sales Forecast by Country (2027-2032)
  5. 8.2 Europe CD40 Ligand Market Size by Country
  6. 8.2.1 Europe CD40 Ligand Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe CD40 Ligand Market Size by Country (2021-2026)
  8. 8.2.3 Europe CD40 Ligand Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific CD40 Ligand Sales by Country
  2. 9.1.1 Asia-Pacific CD40 Ligand Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific CD40 Ligand Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific CD40 Ligand Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific CD40 Ligand Market Size by Country
  6. 9.2.1 Asia-Pacific CD40 Ligand Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific CD40 Ligand Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific CD40 Ligand Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America CD40 Ligand Sales by Country
  2. 10.1.1 South America CD40 Ligand Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America CD40 Ligand Sales by Country (2021-2026)
  4. 10.1.3 South America CD40 Ligand Sales Forecast by Country (2027-2032)
  5. 10.2 South America CD40 Ligand Market Size by Country
  6. 10.2.1 South America CD40 Ligand Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America CD40 Ligand Market Size by Country (2021-2026)
  8. 10.2.3 South America CD40 Ligand Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa CD40 Ligand Sales by Country
  2. 11.1.1 Middle East and Africa CD40 Ligand Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa CD40 Ligand Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa CD40 Ligand Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa CD40 Ligand Market Size by Country
  6. 11.2.1 Middle East and Africa CD40 Ligand Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa CD40 Ligand Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa CD40 Ligand Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 CD40 Ligand Value Chain Analysis
  2. 12.1.1 CD40 Ligand Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 CD40 Ligand Production Mode & Process
  7. 12.2 CD40 Ligand Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 CD40 Ligand Distributors
  10. 12.2.3 CD40 Ligand Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst